Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy

Clinical Cancer Research

Volumn 3, Issue 12 I, 1997, Pages 2471-2478

  Chevillard, Sylvie ^a   Lebeau, Jérôme ^a   Pouillart, Pierre ^b   De Toma, Claudia ^c   Beldjord, Chérif ^c   Asselain, Bernard ^b   Klijanienko, Jerzy ^b   Fourquet, Alain ^b   Magdelénat, Henri ^b   Vielh, Philippe ^b  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b INSTITUT CURIE   (France)

^c CHU Cochin Port Royal ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; THIOTEPA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE S PHASE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; CELL CYCLE; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, MULTIPLE; FEMALE; GENES, P53; HUMANS; MIDDLE AGED; NEOPLASM STAGING; P-GLYCOPROTEIN; POINT MUTATION; POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; S PHASE; SEQUENCE DELETION; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0031427453     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Clark, G. Prognostic and predictive factors. In: J. Harris, M. Lippman, M. Morrow, and S. Hellman (eds.), Diseases of the Breast, pp. 461-486. Philadelphia: Lippincott-Raven, 1996.
2. Harris, C. C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst., 88: 1442-1455, 1996.
3. Hainaut, P., Soussi, T., Shomer, B., Hollstein, M., Greenblatt, M., Hovig, E., Harris, C. C., and Montesano, R. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res., 25: 151-157, 1997.
4. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
5. Hartmann, A., Blaszyk, H., McGovern, R. M., Schroeder, J. J., Cunningham, J., De Vries, E. M., Kovach, J. S., and Sommer, S. S. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene, 10: 681-688, 1995.
6. Cho, Y., Gorina, S., Jeffrey, P. D., and Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (Washington DC), 265: 346-355, 1994.
7. Elledge, R. M., Fuqua, S. A., Clark, G. M., Pujol, P., Allred, D, C., and McGuire, W. L. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res. Treat., 26: 225-235, 1993.
8. Thorlacius, S., Borresen, A. L., and Eyfjord, J. E. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res., 53: 1637-1641, 1993.
9. Andersen, T. I., Holm, R., Nesland, J. M., Heimdal, K. R., Ottestad, L., and Borresen, A. L. Prognostic significance of TP53 alterations in breast carcinoma. Br. J. Cancer, 68: 540-548, 1993.
10. Bergh, J., Norberg, T., Sjogren, S., Lindgren, A., and Holmberg, L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med., 1: 1029-1034, 1995.
11. Kovach, J. S., Hartmann, A., Blaszyk, H., Cunningham, J., Schaid, D., and Sommer, S. S. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc. Natl. Acad. Sci. USA, 93: 1093-1096, 1996.
12. Aas, T., Borresen, A. L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., and Lonning, P. E. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med., 2: 811-814, 1996.
13. Chin, K. V., Ueda, K., Pastan, I., and Gottesman, M. M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science (Washington DC), 255: 459-462, 1992.
14. Zastawny, R. L., Salvino, R., Chen, J., Benchimol, S., and Ling, V. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene, 8: 1529-1535, 1993.
15. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., and Levine, A. J. Gain of function mutations in p53. Nat. Genet., 4: 42-46, 1993.
16. Nguyen, K. T., Liu, B., Ueda, K., Gottesman, M. M., Pastan, I., and Chin, K. V. Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol. Res., 6: 71-77, 1994.
17. Chevillard, S., Pouillart, P., Beldjord, C., Asselain, B., Beuzeboc, P., Magdelénat, H., and Vielh, P. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer (Phila.), 77: 292-300, 1996.
18. Hermanek, P., and Sobin, L. TNM Classification of Malignant Tumours, 5th ed. Berlin: Springer Verlag, 1997.
19. Bloom, H. J., and Richardson, W. W. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed 15 years. Br. J. Cancer, 11: 359-377, 1957.
20. Vielh, P., Magdelénat, H., Mosseri, V., Remvikos, Y., and Di Bonito, L. Immunocytochemical determination of estrogen and progesterone receptors on 50 fine-needle samples of breast cancer: a prospective study including biochemical correlation and DNA flow cytometric analysis. Am. J. Clin. Pathol., 97: 254-261, 1992.
21. Harris, J., Morrow, M., and Bonadonna, G. Cancer of the breast. In: V. J. DeVita, S. Hellman, and S. Rosenberg (eds.), Cancer: Principles & Practice of Oncology, 4th ed., pp. 1264-1332. Philadelphia: J. B. Lippincott Co., 1993.
22. Myers, R. M., Lumelsky, N., Lerman, L. S., and Maniatis, T. Detection of single base substitutions in total genomic DNA. Nature (Lond.), 313: 495-498, 1985.
23. Lerman, L. S. Detecting sequence changes in a gene. Somatic Cell Mol. Genet., 13: 419-422, 1987.
24. Costes, B., Girodon, E., Ghanem, N., Chassignol, M., Thuong, N. T., Dupret, D., and Goossens, M. Psoralen-modified oligonucleotide primers improve detection of mutations by denaturing gradient gel electrophoresis and provide an alternative to GC-clamping. Hum. Mol. Genet., 2: 393-397, 1993.
25. Myers, R. M., Fischer, S. G., Lerman, L. S., and Maniatis, T. Nearly all single base substitutions in DNA fragments joined to a GC-clamp can be detected by denaturing gradient gel electrophoresis. Nucleic Acids Res., 13: 3131-3145, 1985.
26. Sheffield, V. C., Cox, D. R., Lerman, L. S., and Myers, R. M. Attachment of a 40-base-pair G + C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes. Proc. Natl. Acad. Sci. USA, 86: 232-236, 1989.
27. Bartek, J., Iggo, R., Gannon, J., and Lane, D. P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene, 5: 893-899, 1990.
28. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F., Western, A., Modali, R., Harris, C., and Vogelstein, B. Mutations in the p53 gene occur in diverse human tumour types. Nature (Lond.), 342: 705-708, 1989.
29. Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B., Bodmer, W. F., Gannon, J. V., and Lane, D. P. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA, 87: 7555-7559, 1990.
30. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
31. Peto, R., and Peto, J. Asymptomatically efficient rank invariant test procedures. J. R. Stat. Soc. A., 135: 185-198, 1972.
32. Hartmann, A., Blaszyk, H., Kovach, J. S., and Sommer, S. S. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet., 13: 27-33, 1997.
33. Caleffi, M., Teague, M. W., Jensen, R. A., Vnencak-Jones, C. L., Dupont, W. D., and Pari, F. F. p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer (Phila.), 73: 2147-2156, 1994.
34. Shiao, Y. H., Chen, V. W., Scheer, W. D., Wu, X. C., and Correa, P. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res., 55: 1485-1490, 1995.
35. Gretarsdottir, S., Tryggvadottir, L., Jonasson, J. G., Sigurdsson, H., Olafsdottir, K., Agnarsson, B. A., Ogmundsdottir, H., and Eyfjord, J. E. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br. J. Cancer, 74: 555-561, 1996.
36. Ory, K., Legros, Y., Auguin, C., and Soussi, T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J., 13: 3496-3504, 1994.
37. Mazars, R., Spinardi, L., BenCheikh, M., Simony-Lafontaine, J., Jeanteur, P., and Theillet, C. p53 mutations occur in aggressive breast cancer. Cancer Res., 52: 3918-3923, 1992.
38. Cervantes, M., Zhou, H., Sahin, A., Dhingra, K., Valero, V., Ordonez, N., El-Naggar, A., Hess, K., Glassman, A., and Sen, S. p53 alterations show significant correlation with gene amplification and high S-phase index in breast cancer. Int. J. Oncol., 6: 955-962, 1995.
39. Lipponen, P., Ji, H., Aaltomaa, S., Syrjanen, S., and Syrjanen, K. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int. J. Cancer, 55: 51-56, 1993.
40. Jacquemier, J., Moles, J. P., Penault-Llorca, F., Adelaide, J., Torrente, M., Viens, P., Birnbaum, D., and Theillet, C. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br. J. Cancer, 69: 846-852, 1994.
41. Isola, J., Visakorpi, T., Holli, K., and Kallioniemi, O. P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Natl. Cancer Inst., 84: 1109-1114, 1992.
42. Allred, D. C., Clark, G. M., Elledge, R., Fuqua, S. A., Brown, R. W., Chamness, G. C., Osborne, C. K., and McGuire, W. L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst., 85: 200-206, 1993.
43. Merlo, G. R., Bernardi, A., Diella, F., Venesio, T., Cappa, A. P., Callahan, R., and Liscia, D. S. In primary human breast carcinomas mutations in exons 5 and 6 of the p53 gene are associated with a high S-phase index. Int. J. Cancer, 54: 531-535, 1993.
44. Strauss, B. E., and Haas, M. The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant p53 proteins. Biochem. Biophys. Res. Commun., 217: 333-340, 1995.
45. Goldsmith, M. E., Gudas, J. M., Schneider, E., and Cowan, K. H. Wild-type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J. Biol. Chem., 270: 1894-1898, 1995.
46. Preudhomme, C., Lepelley, P., Vachee, A., Soenen, V., Quesnel, B., Cosson, A., and Fenaux, P. Relationship between p53 gene mutations and multidrug resistance (mdr1) gene expression in myelodysplastic syndromes. Leukemia (Baltimore), 7: 1888-1890, 1993.
47. el Rouby, S., Thomas, A., Costin, D., Rosenberg, C. R., Potmesil, M., Silber, R., and Newcomb, E. W. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood, 82: 3452-3459, 1993.
48. Schneider, J., Rubio, M. P., Barbazan, M. J., Rodriguez-Escudero, F. J., Seizinger, B. R., and Castresana, J. S. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J. Natl. Cancer Inst., 86: 850-855, 1994.
49. De Angelis, P., Stokke, T., Smedshammer, L., Lothe, R. A., Lehne, G., Chen, Y., and Clausen, O. P. P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br. J. Cancer, 72: 307-311, 1995.
50. Charpin, C., Vielh, P., Duffaud, F., Devictor, B., Andrac, L., Lavaut, M. N., Allasia, C., Horschowski, N., and Piana, L. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J. Natl. Cancer Inst., 86: 1539-1545, 1994.
51. Linn, S. C., Honkoop, A. H., Hoekman, K., van der Volk, P., Pinedo, H. M., and Giaccone, G. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br. J. Cancer, 74: 63-68, 1996.
52. Casey, G., Lopez, M. E., Ramos, J. C., Plummer, S. J., Arboleda, M. J., Shaughnessy, M., Karlan, B., and Slamon, D. J. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene, 13: 1971-1981, 1996.
53. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington, DC), 266: 807-810, 1994.
54. Elledge, R. M., Gray, R., Mansour, E., Yu, Y., Clark, G. M., Ravdin, P., Osborne, C. K., Gilchrist, K., Davidson, N. E., and Robert, N. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J. Natl. Cancer Inst., 87: 1254-1256, 1995.
55. Moll, U. M., Ostermeyer, A. G., Ahomadegbe, J. C., Mathieu, M. C., and Riou, G. p53-mediated tumor cell response to chemotherapeutic DNA damage: a preliminary study in matched pairs of breast cancer biopsies. Hum. Pathol., 26: 1293-1301, 1995.
56. Ellis, P. A., Smith, I. E., McCarthy, K., Detre, S., Salter, J., and Dowsett, M. Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet, 349: 849, 1997.
57. Wosikowski, K., Regis, J. T., Robey, R. W., Alvarez, M., Buters, J. T., Gudas, J. M., and Bates, S. E. Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ., 6: 1395-1403, 1995.